TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an update.
Ascletis Pharma Inc. announced promising preclinical results for its obesity treatment drug candidates, ASC47 and ASC31, demonstrating significant weight loss in an animal model. The combination of these drugs showed a 44.8% reduction in body weight, outperforming a similar combination with tirzepatide, indicating potential differentiation in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology company focused on developing innovative therapies for the treatment of obesity and other metabolic diseases. The company specializes in creating small molecules and peptide-based drugs, leveraging its Ultra-Long-Acting Platform (ULAP) for novel subcutaneously injectable and oral peptides.
Average Trading Volume: 6,158,972
Technical Sentiment Signal: Buy
Current Market Cap: HK$17.2B
See more data about 1672 stock on TipRanks’ Stock Analysis page.